Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps  Latest publication
mAB 2-17
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
CoV-X2
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/25/2021
WNbFc 7
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/23/2021
Plerixafor
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Mar/23/2021
mAB 4-18
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
Temsirolimus
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Mar/25/2021
ACE2‐TMPRSS2‐EVs
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/28/2020
TPNT1
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/22/2021
P2B-2F6
Potential treatment - pre-clinical evidence Experimental Antiviral May/26/2020
WNbFc 2
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/23/2021
N-[(2R)-2-(1H-Indol-3-yl)-2-thiophen-2-ylethyl]-2-oxo-1H-quinoline-4-carboxamide
Potential treatment - theoretical effect Experimental Antiviral Dec/17/2020
Silymarin
Potential treatment - pre-clinical evidence Natural product Antiviral Mar/05/2021
mAB 5-24
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
Everolimus
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Mar/25/2021
FN3D
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/05/2021
P2C-1F11
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/25/2022
Sciadopitysin
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/22/2021
Silibinin
Potential treatment - theoretical effect Natural product Antiviral Apr/06/2021
Torin 2
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/25/2021
mAB 1-87
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021